PV Bulletin

Product Management Service (PMS) public API beta release - Technical registration requirements

EMA released updated technical registration requirements for the PMS public API beta release, affecting marketing authorization holders' data management systems.

Primary source: Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (II-40)

PV Impact Brief

Urgency: HighConfidence: high

What changed

The EMA released updated technical registration requirements for the PMS public API, mandating MAHs to review and ensure system compatibility with these requirements for effective data submission.

Why it matters

Compliance with the new API requirements is necessary for accurate pharmacovigilance reporting, including vital ICSR/E2B identifiers, impacting the integrity of regulatory data management.

Action needed

MAHs and technical teams must review the revised API registration requirements and implement necessary system updates to comply by the established timelines.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country ComplianceICSR
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Technical Guidance
Policy status
beta
Publication date
12 June 2026
Policy change
EMA released updated technical registration requirements and API documentation (Chapter 1, Annex B) for the Product Management Service (PMS) public API beta release. This is part of the ongoing implementation of ISO IDMP standards for the identification of medicinal products in Europe.

Key changes

Release of technical specifications for public PMS API registration; Annex B updates for ISO IDMP implementation; registration requirements for beta and production environments for substance and product data management.

Affected workflows

Country ComplianceICSR

Responsible groups

Regulatory OperationsITPV Data Management

PV impact

Marketing Authorization Holders (MAHs) and technical teams responsible for regulatory data management must review the new registration requirements to ensure their systems can integrate with the PMS API. This affects the submission of master data which is critical for pharmacovigilance reporting (e.g., ICSR/E2B identifiers).

View regulator source

Source document details

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 12, 2026

Full briefing

Practical implication

MAHs and technical teams must review the revised API registration requirements and implement necessary system updates to comply by the established timelines.

The EMA has updated the technical registration requirements and API documentation for the PMS public API beta release. Marketing Authorization Holders (MAHs) must review these requirements to ensure their systems are compatible with the API, which is critical for pharmacovigilance reporting, particularly regarding ICSR/E2B identifiers.

What changed: The EMA released updated technical registration requirements for the PMS public API, mandating MAHs to review and ensure system compatibility with these requirements for effective data submission.

Why it matters: Compliance with the new API requirements is necessary for accurate pharmacovigilance reporting, including vital ICSR/E2B identifiers, impacting the integrity of regulatory data management.

Practical implication: MAHs and technical teams must review the revised API registration requirements and implement necessary system updates to comply by the established timelines.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Technical Guidance#beta#European Medicines Agency (EMA)#reporting_requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward